论文部分内容阅读
Gefitinib is used as a first-line treatment for advanced non-small cell lung cancer(NSCLC).Unfortunately,most NSCLC patients inevitably develop gefitinib resistance during treatment.In addition to EGFR mutation status,the mechanisms involved are largely u